Find your next paid study

MOMA TherapeuticsNCT06545942

Phase 1

A Phase I Study to Determine the Preferred Dose of the Angiotensin Converting Enzyme Inhibitor Lisinopril for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer

This study will establish the preferred dose of lisinopril in men with non-metastatic prostate cancer undergoing radiation treatment. This study will also eval…

Prostate CancerRadiation ToxicityUrinary Complication

University of RochesterNCT05530655

Phase 1

Imaging of Solid Tumors Using 18F-TRX

This phase I trial tests the safety and effectiveness of 18F-TRX in detecting tumors (cancer) patients with solid tumors. 18F-TRX is an imaging tracer that is …

Solid TumorSolid CarcinomaCastration-Resistant Prostate Carcinoma+7 more

Rahul AggarwalNCT06942104

Observational

The Florida Partnership for Adding Social Context to Address Cancer Survivorship Outcomes (Florida ASCENT)

The goal of this clinical trial is to adapt, implement, and evaluate MyCarePulse and ASCENT patient navigator to overcome barriers to care among patients with …

CancerFood DeprivationFood Habits+11 more

University of FloridaNCT07042243

Phase 2

Integration of FTT-PET and ctDNA to Predict Response to PARP Inhibitor Therapy in Metastatic Prostate Cancer (mPC)

This multicenter center, open-label, baseline-controlled diagnostic imaging study designed to assess the use of Fluorthanatrace-Positron Emission tomography (F…

Metastatic Prostate CancerProstate Cancer

Washington University School of MedicineNCT07723651

Phase 3

A Single Arm, Multicenter, Prospective, Open Label, Longitudinal Phase 3 Study of Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) Combined With Magnetic Resonance Imaging (MRI) Compared to Standard of Care (SOC) for the Detection of Prostate Cancer (PCa).

This is an open label, longitudinal Phase 3 study of prostate specific membrane antigen (PSMA) positron emission tomography (PET) combined with magnetic resona…

PCAProstate CancerProstatic Neoplasm+6 more

Telix Pharmaceuticals (Innovations) Pty LimitedNCT07052214

Phase 1

Phase I Non-Randomized, Unblinded, Single-Center Trial of Oral Telmisartan Alone or Combined With Selected Standard of Care Therapies for Prostate Cancer

The goal of this clinical trial is to learn about the tolerability of telmisartan in patients with prostate cancer, but evidence for treatment efficacy will al…

Prostate Cancer

Tyler J CurielNCT06168487

~$10 – $7,500

Observational

Focal Prostate Ablation for Low to Intermediate Grade Cancer Utilizing TULSA Profound System

This clinical trial tests whether the magnetic resonance imaging (MRI)-guided transurethral ultrasound ablation (TULSA) procedure is safe and effective in trea…

Prostate CarcinomaStage I Prostate Cancer AJCC v8Stage II Prostate Cancer AJCC v8

Androgen Axis SuppressionProstatectomyProstate Cancer

Mayo ClinicNCT05438563

Phase 3

PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.

1. Personalize treatment for prostate cancer based on how aggressive the disease is and 2. Learn if apalutamide-based treatment can help to reduce fatigue and …

M.D. Anderson Cancer CenterNCT06274047

Phase 4

Safety of Intramuscular Testosterone Replacement Therapy in Hypogonadal Patients With Prostate Cancer Under Active Surveillance

The purpose of this study is evaluate the safety of testosterone replacement therapy in men with newly diagnosed low-risk prostate cancer and hypogonadism on a…

Prostate CancerHypogonadism, Male

University of MiamiNCT07278362

Observational

Low-Count Quantitative SPECT for Men Treated With Radium-223

Internal radiotherapies (radiolabeled molecules that are systemically administered and localize to sites of disease) provide cancer-ablating doses to diseased …

Prostate CancerCancer of the Prostate

Washington University School of MedicineNCT07221825

Phase 3

A Multinational, Multicenter, Prospective, Randomized, Controlled, Open-Label, Phase 3 Study of Lutetium (177Lu) Rosopatamab Tetraxetan in Combination With Standard of Care Versus Standard of Care Alone in Patients With PSMA Positive Metastatic Castration-Resistant Prostate Cancer Previously After Androgen Receptor Pathway Inhibitor Treatment

The purpose of this study is to evaluate the efficacy and safety of 177Lu-TLX591 in patients with metastatic castration-resistant prostate cancer who have prog…

Metastatic Castration-resistant Prostate Cancer